Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations.
Recent studies have shown that the release properties of vincristine encapsulated in large unilamellar vesicles (LUV) can be regulated by varying the drug-to-lipid (D/L) ratio. In this work it is shown that the drug-to-lipid ratio technique for regulating drug release also applies to doxorubicin encapsulated in LUV. In particular it is shown that the half-times (T(1/2)) for doxorubicin release from distearoylphosphatidylcholine (DSPC)/cholesterol LUV in vitro can be increased more than six-fold by increasing the D/L ratio from 0.05 (wt/wt) to 0.39 (wt/wt). This behavior is consistent with the behavior expected for drugs that precipitate following accumulation into liposomes. It is shown that the release properties of ciprofloxacin--a drug that does not precipitate following accumulation into LUV--are not affected by the D/L ratio. It is also shown that the crystalline intravesicular doxorubicin precipitates observed as the D/L ratio is raised from 0.05 to 0.46 adopt increasingly unusual morphologies. Linear crystals are observed at lower D/L values, however triangular and rectangular variations are observed as the D/L ratio is increased, and induce considerable distortion in vesicle morphology. It is noted that trapping efficiency following uptake of external doxorubicin into LUV is reduced from nearly 100% at a D/L ratio of 0.05 (wt/wt) to less than 70% at an (initial) D/L ratio of 0.8 (wt/wt). It is suggested that this arises, at least in part, from membrane-disrupting effects of internal drug crystals as they increase in size.
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.
Michael J W
MJ
Johnston
Katarina
K
Edwards
Goran
G
Karlsson
Pieter R
PR
Cullis
D000890:Anti-Infective Agents / Q000737:chemistry; D000903:Antibiotics, Antineoplastic / Q000737:chemistry*; D002784:Cholesterol / Q000737:chemistry*; D002939:Ciprofloxacin / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000737:chemistry; D004317:Doxorubicin / Q000737:chemistry*; D008081:Liposomes; D010316:Particle Size; D010713:Phosphatidylcholines / Q000737:chemistry*
D000890:Anti-Infective Agents; D000903:Antibiotics, Antineoplastic; D003692:Delayed-Action Preparations; D008081:Liposomes; D010713:Phosphatidylcholines; D002939:Ciprofloxacin; D004317:Doxorubicin; D002784:Cholesterol; C010942:1,2-distearoyllecithin